ENOV at a glance
Enovis CORP (ENOV, SEC CIK 1420800) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 1, 2026 and Form 4 insider filings as recently as October 1, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Enovis CORP (ENOV) reported revenue of $2.2 billion (up 6.7% from FY2024) and a net loss of $1.2 billion. Diluted EPS was -$20.75.
- As of June 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Enovis CORP (ENOV) shares worth $641.6 million in 13F-HR filings.
- The most recent insider open-market purchase reported on Form 4 was by McDonald Damien on September 4, 2026 of 13,035 shares at $19.15 per share.
- In the last 90 days, ENOV insiders reported 4 open-market purchases ($450K) and 0 open-market sales ($0) on Form 4, a net purchase of $450K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $2.2B
- +6.7% vs prior year
- Insiders · 90 days
- 4 buys · 0 sells
- Net +$450K
- 13F holders
- 29 funds
- $641.6M · −3 vs prior quarter
- Latest 8-K
- Sep 1, 2026
- Item 7.01
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Risk Factors
- Sarbanes-Oxley Act compliance risk from failed internal control integration at acquisitions, e.g., Lima Acquisition, possibly causing material misstatements in financial reports
- Geopolitical risk from supply chain in China and Asia; political instability risks disrupting access to raw materials critical to manufacturing
- Manufacturing disruption risk from equipment failure, natural disasters, terrorism, labor shortages affecting facility operations and customer order fulfillment
- Competitive risk from superior rival technologies and products; competitors with greater resources could cause market share loss and pricing pressure
- Financial risk of $1.7B+ outstanding debt subject to restrictive covenants limiting transactions and increasing vulnerability to economic downturns
Management Discussion & Analysis
- Revenue $2.248B, up 5.1% YoY: P&R $1.137B (+$39M), Recon $1.111B (+$101.4M)
- Operating loss margin worsened: P&R (32.9)% vs (29.3)%, Recon (67.5)% vs (45.0)% in 2024 due to goodwill impairments ($387.8M P&R, $662M Recon)
- Best segment Recon: Adjusted EBITDA $239.9M (+$23M), margin stable 21.6% vs 21.5%; worst P&R operating loss margin (32.9)%
- Cash flow: Operating cash flow $217.3M (+$103.8M), CapEx $197.4M, acquisitions $26.9M; Financing used $52.4M including $3.5M buybacks; $36.4M cash on hand
- Forward outlook: Credit facility increased to $1.1B revolver and $700M term loan; Senior secured leverage ratio covenant of 3.50:1; risks from goodwill impairments and acquisition integration costs
Business Overview
- Core business model: Orthopedic solutions via two segments; Prevention & Recovery (P&R) and Reconstructive (Recon) with global manufacturing and sales
- New emphasis on Recon segment growth via $865.6M Lima acquisition in Jan 2024, adding digital innovation and customized hardware
- Strategic shift: Divested Dr Comfort Footcare Solutions in Oct 2025; focus sharpened on direct sales integration and streamlined global operations
- Notable metric: Net sales grew 6.7% to $2.248B in 2025, driven by existing business growth and favorable currency, despite $17.3M sales loss from divestitures
- Unusual fact: Reported $1.05B goodwill impairment charge in 2025, a significant non-cash expense impacting operating loss and net loss margins
AI summary of the ENOV 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jul 3, 2026
Management Discussion & Analysis
- Quarterly revenue $582.7M, up $18.1M or 3.2% YoY, led by Reconstructive growth
- Reconstructive revenue $294.5M, up 7.5%; gross margin 66.2% vs 64.1% YoY
- Prevention & Recovery revenue $288.2M, down 0.8%; gross margin 57.0% vs 54.8% YoY
- Cash $12.6M, down $23.8M from December 31, 2025; operating cash flow $99.0M vs $46.2M YoY
- Capital deployment: $96.7M property, plant and equipment and intangible purchases; $15.0M net debt repayments
Risk Factors
- No risk-factors section provided in the submitted text
- Submitted material covers unregistered sales, senior-security defaults, mine-safety disclosures, trading arrangements, exhibits, and signatures
- No new, updated, regulatory, operational, competitive, market, or financial risks identifiable from provided text
AI summary of the ENOV 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item EX-99.1: Item EX-99.1
- Binding offer to acquire eCential Robotics for €155 million upfront enterprise value and approximately €176 million cash consideration
- Additional contingent consideration of up to €35 million tied to milestone achievement
Item 7.01: Regulation FD Disclosure
- Proposed acquisition of eCential Robotics, developer of surgical robotics and enabling technologies
- Enterprise value approximately €155M, with €176M upfront cash consideration
Item 2.02: Results of Operations and Financial Condition
- Q2 fiscal 2026 results for quarter ended July 3, 2026
- Press release issued August 6, 2026, with detailed financial results in Exhibit 99.1
Item 5.07: Submission of Matters to a Vote of Security Holders
- Ten director nominees elected; closest margin for A. Clayton Perfall, with 50,959,268 votes for and 805,763 against
- Ernst & Young LLP appointment ratified for fiscal year ending December 31, 2026, supporting auditor continuity
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Stockholders approved 3,650,000 additional shares for issuance under Enovis’s 2020 Omnibus Incentive Plan
- Potential dilution increases as newly authorized shares become available for equity compensation
AI summaries of ENOV 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for ENOV
Don't miss the next ENOV filing
- Alerts as it files. A push when ENOV files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut ENOV, by share count.
- Ask anything. An AI agent that reads every ENOV filing and answers with sources.
ENOV alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Ortiz Christine | A | Sep 30, 2026 | 958 | - |
| McDonald Damien | Buy | Sep 4, 2026 | 13,035 | $19.15 |
| Engert Oliver | Buy | Sep 4, 2026 | 2,660 | $18.80 |
| Engert Oliver | Buy | Sep 3, 2026 | 5,140 | $19.46 |
| Engert Oliver | Buy | Sep 2, 2026 | 2,458 | $20.32 |
| Ortiz Christine | A | Jun 30, 2026 | 846 | - |
| Engert Oliver | Buy | Jun 15, 2026 | 1,000 | $20.92 |
| Engert Oliver | Buy | Jun 11, 2026 | 1,000 | $21.75 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $2.1B | $2.2B |
| Gross Profit | - | $1.2B | $1.3B |
| Operating Income | - | -$775.7M | -$1.1B |
| Net Income | - | -$825.5M | -$1.2B |
| Gross Margin | - | 56.0% | 59.8% |
| Op. Margin | - | -36.8% | -50.0% |
| Net Margin | - | -39.2% | -52.7% |
| Balance Sheet | |||
| Total Assets | $4.5B | $4.7B | $3.8B |
| Equity | $3.4B | $2.6B | $1.5B |
| ROE | - | -32.2% | -79.5% |
| Per Share | |||
| EPS | - | $-14.93 | $-20.75 |
| Cash Flow | |||
| Operating CF | - | $113.5M | $217.3M |
| CapEx | - | $180.7M | $197.4M |
Source: XBRL data in Enovis CORP (ENOV)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate ENOV share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 29 | $641.6M |
| Q1 2026 | 32 | $695.4M |
| Q4 2025 | 29 | $773.4M |
| Q3 2025 | 30 | $880.9M |
| Q2 2025 | 27 | $904.7M |
| Q1 2025 | 23 | $665.0M |
| Q4 2024 | 20 | $624.6M |
| Q3 2024 | 20 | $381.7M |
- FMR LLC (Fidelity)+846.2K (+62%)
- Citigroup+375.5K (+3865%)
- BlackRock+359.2K (+4%)
- AQR Capital Management+306.7K (+108%)
- Goldman Sachs Group+204.4K (+13%)
- Dimensional Fund Advisors−801.0K (-31%)
- JPMorgan Chase & Co−372.6K (-90%)
- Bank of America Corp−130.0K (-19%)
- Vanguard Capital Management LLC−68.0K (-3%)
- Raymond James Financial−42.5K (-21%)
- Allstate+31.2K
- Citadel Advisors LLC−781.8K
- Marex Group plc−15.3K
- Franklin Resources−11.7K
- Truist Financial−11.7K
Source: 13F-HR filings on SEC EDGAR (aggregated from 210 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
ENOV filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Oct 1, 2026 | - | - | - |
| 4 | Sep 8, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 4 | Sep 4, 2026 | - | - | - |
| 8-K | Sep 1, 2026 | - | Analysis | - |
| SC 13G | Aug 14, 2026 | - | - | |
| 8-K | Aug 6, 2026 | - | Analysis | - |
| 10-Q | Aug 6, 2026 | Jul 3, 2026 | Analysis | |
| 4 | Jul 1, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 16, 2026 | - | - | - |
| 4 | Jun 15, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 4 | May 21, 2026 | - | - | |
| 8-K | May 19, 2026 | - | Analysis | |
| 4 | May 14, 2026 | - | - | |
| 4 | May 14, 2026 | - | - |
Related Health Care companies
- ALGN · Align TechnologyOrthopedic, Prosthetic & Surgical Appliances & Supplies
- AVR · Anteris Technologies Global Corp.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- AVNS · AVANOS MEDICAL, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
- EW · Edwards LifesciencesOrthopedic, Prosthetic & Surgical Appliances & Supplies
- INGN · Inogen IncOrthopedic, Prosthetic & Surgical Appliances & Supplies
- ISRG · Intuitive SurgicalOrthopedic, Prosthetic & Surgical Appliances & Supplies
- LAKE · LAKELAND INDUSTRIES INCOrthopedic, Prosthetic & Surgical Appliances & Supplies
- MYO · MYOMO, INC.Orthopedic, Prosthetic & Surgical Appliances & Supplies
ENOV SEC filings: frequently asked questions
Are ENOV insiders buying or selling?
In the last 90 days, Enovis CORP (ENOV) officers, directors and 10% owners reported 4 open-market purchases worth $449,599 by 2 insiders and no open-market sales on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold ENOV stock?
As of June 30, 2026, the largest Enovis CORP (ENOV) holders among the 13F filers tracked by SignalX were BlackRock ($213.1 million), Vanguard Portfolio Management LLC ($81.3 million), Vanguard Capital Management LLC ($51.4 million), State Street Corp ($51.0 million), FMR LLC (Fidelity) ($45.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was ENOV's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Enovis CORP (ENOV) reported revenue of $2.2 billion (up 6.7% from FY2024) and a net loss of $1.2 billion. Diluted EPS was -$20.75. The figures come from the XBRL data in the 10-K.
What are the main risks in ENOV's latest 10-K?
In the 10-K filed February 26, 2026, Enovis CORP (ENOV) flagged: Sarbanes-Oxley Act compliance risk from failed internal control integration at acquisitions, e.g., Lima Acquisition, possibly causing material misstatements in financial reports. Geopolitical risk from supply chain in China and Asia; political instability risks disrupting access to raw materials critical to manufacturing. (AI summary of the Risk Factors section.)
What did ENOV report in its latest 8-K?
Enovis CORP (ENOV) filed an 8-K on September 1, 2026 reporting Item 7.01 (Regulation FD Disclosure). Binding offer to acquire eCential Robotics for €155 million upfront enterprise value and approximately €176 million cash consideration.
What are the latest ENOV SEC filings?
Enovis CORP (ENOV) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on August 6, 2026, an 8-K current report on September 1, 2026 and a Form 4 insider filing on October 1, 2026.
What is ENOV's SEC CIK number?
Enovis CORP (ENOV)'s SEC Central Index Key (CIK) is 1420800. EDGAR lists every ENOV filing under that number.
Ask anything about ENOV
The research agent reads ENOV's filings, financials, insider trades and 13F holders, then answers with sources.